Jianjia Healthcare Launches New Chain Brand 'Jianjia Rehabilitation', Injecting Fresh Momentum into China's Rehabilitation Industry
In recent years, with the continuous intensification of population aging and the growing number of patients with chronic diseases in China, the demand for rehabilitation medical services has been increasing. As one of the four major branches of medicine, rehabilitation medicine is playing an increasingly prominent role in meeting the public’s health needs and improving quality of life.
On November 11, at the 2023 Comprehensive Academic Annual Conference of the Chinese Association of Rehabilitation Medicine, the rehabilitation industry welcomed another major player. Jianjia Medical Investment Management Co., Ltd. (formerly “Sinopharm Holding Medical Investment Management Co., Ltd.”; hereinafter referred to as “Jianjia Medical”) officially launched its chain rehabilitation brand, “Jianjia Rehabilitation,” drawing significant attention from the industry.
Peng Mingqiang, Party Secretary and Executive Vice President of the Chinese Association of Rehabilitation Medicine; Niu Enxi, Chairman of the Board of Supervisors and Full-time Deputy Party Secretary of the Chinese Association of Rehabilitation Medicine; Fang Guoen, Chairman of the Expert Committee of the Chinese Association of Rehabilitation Medicine; Li Yunbo, Secretary-General of the Chinese Association of Rehabilitation Medicine; Zhu Wenkui, Party Secretary of Fosun Group and Vice President of Fosun International; Chen Yuqing, Vice President of Fosun International and Chairman of Fosun Health and Jianjia Medical; Wei Yulin, Senior Vice President of Fosun Pharma and Executive Director and CEO of Jianjia Medical; Hu Hang, Senior Vice President of Fosun Pharma and CEO of Fosun Health; and Feng Jie, General Manager of Jianjia Medical, jointly launched the new brand for Jianjia Rehabilitation.
The official launch of the “Jianjia Rehabilitation” brand marks Jianjia Medical’s future commitment to focusing squarely on the rehabilitation sector, striving to become a reputable, high-quality, technologically advanced, and innovatively driven rehabilitation healthcare group within China’s broader health industry, thereby actively promoting the development of the nation’s rehabilitation medical sector.
Jianjia Medical, established in 2013, is an investment and operational management platform specializing in integrated solutions for continuous rehabilitative care, professional nursing, and daily living assistance. With a registered capital of RMB 1 billion, the company is headquartered in Shanghai and was jointly founded by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Sinopharm Holding Co., Ltd. As of September 2023, Jianjia Medical operates 20 affiliated hospitals with a total gross floor area of 500,000 square meters and more than 8,000 beds. Among these, 15 are rehabilitation hospitals with 5,200 beds, covering 12 cities across 8 provinces, including key regions and cities such as Shanghai, Beijing, Tianjin, Nanchang, Hangzhou, Fuzhou, Wuhan, Nanjing, Yangzhou, Bengbu, Xuzhou, and Kunshan.
The integration of health and wellness constitutes a core component of modern rehabilitation medicine and serves as a vital pathway to promote high-quality development in rehabilitation healthcare and meet the growing demand for rehabilitation services. With the continuous rise in market demand, modern, specialized, and high-quality rehabilitation medical institutions have become the inevitable choice for the general public, thereby raising higher expectations for professional standards and service capabilities. The rehabilitation hospitals under Jianjia Medical adhere to an organizational management model characterized by “standardization, digitalization, productization, and integration,” continuously establishing benchmark hospital development models and pursuing high-quality innovative growth. Following the launch of its new brand, Jianjia Medical will further invest and expand according to a nationwide layout and a “multiple sites per city” strategy, providing local patients with more convenient and superior rehabilitation medical services. This initiative will undoubtedly foster the advancement of rehabilitation medicine in China and contribute industry strength to enhancing the health and well-being of the population.